Garret Parker, MD
Internal Medicine · Omaha, NENPI 1194875195
Payments from drug & device makers
Across 245 payments — averaging $15.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$892
- AbbVie$458
- Lilly USA, LLC$294
- Bayer$271
- GSK$253
- Amgen$249
- plus $1K from 27 others
What the payments were for
- Consulting fees$201%
- Speaking & faculty fees$251%
- Food & beverage$3,65399%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 60 | $892 |
| AbbVie(2 entities) | 27 | $458 |
| Lilly USA, LLC | 18 | $294 |
| Bayer | 18 | $271 |
| GSK | 26 | $253 |
| Amgen | 17 | $249 |
| Pfizer | 11 | $187 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 9 | $137 |
| AstraZeneca | 8 | $106 |
| Astellas Pharma US Inc | 6 | $100 |
| Biohaven Pharmaceuticals, Inc. | 4 | $78 |
| Amarin Pharma, Inc. | 5 | $74 |
| Sumitomo Pharma America, Inc. | 3 | $64 |
| Johnson & Johnson | 4 | $61 |
| LEO Pharma Inc. | 3 | $54 |
| Inspire Medical Systems, Inc. | 1 | $45 |
| Sanofi-aventis U.S. LLC | 2 | $42 |
| Idorsia Pharmaceuticals US Inc | 3 | $38 |
| Kowa Pharmaceuticals America, Inc. | 3 | $35 |
| Ultragenyx Pharmaceutical Inc. | 2 | $34 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $34 |
| Novartis | 1 | $28 |
| Boehringer Ingelheim | 2 | $26 |
| Abbott | 1 | $25 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $16 |
| Axsome Therapeutics, Inc. | 1 | $15 |
| Amneal Pharmaceuticals LLC | 1 | $14 |
| Genentech USA, Inc. | 1 | $14 |
| Xeris Pharmaceuticals, Inc. | 1 | $13 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $12 |
| Merck | 1 | $12 |
| Esperion Therapeutics, Inc. | 1 | $11 |
| Phathom Pharmaceuticals, Inc. | 1 | $8 |
How this compares
$3,698 in reported general payments places this provider in the 85th percentile of 570 internal medicine providers in Nebraska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 78 | $95,038 |
| MounjaroTirzepatide | 66 | $71,561 |
| EliquisApixaban | 81 | $61,674 |
| JanuviaSitagliptin Phosphate | 27 | $33,572 |
| TrulicityDulaglutide | 26 | $33,218 |
| OzempicSemaglutide | 36 | $32,718 |
| FarxigaDapagliflozin Propanediol | 35 | $25,324 |
| Tresiba Flextouch U-200Insulin Degludec | 28 | $24,018 |
| Repatha SureclickEvolocumab | 18 | $23,293 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 15 | $19,531 |
| XareltoRivaroxaban | 15 | $18,640 |
| RybelsusSemaglutide | 12 | $11,173 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 12 | $9,931 |
| MyrbetriqMirabegron | 13 | $9,441 |
| Breo ElliptaFluticasone/Vilanterol | 14 | $5,704 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $294 | $104,77992 claims |
| Boehringer IngelheimJardiance, Combivent Respimat | $26 | $100,57989 claims |
| PfizerEliquis | $187 | $61,67481 claims |
| Novo NordiskOzempic, Rybelsus | $892 | $43,89148 claims |
| MerckJanuvia | $12 | $33,57227 claims |
| AstraZenecaFarxiga, Symbicort | $106 | $29,40450 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $253 | $25,23429 claims |
| Johnson & JohnsonXarelto | $61 | $18,64015 claims |
| Astellas Pharma US IncMyrbetriq | $100 | $9,44113 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $14 | $1,423201 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 570 internal medicine providers in Nebraska.
Other internal medicine in Omaha
- Michael DunnOmaha$7.9M
- Joel MichalskiOmaha$1.6M
- Ariana BauerOmaha$1.5M
- David CrockettOmaha$821K
- Bryant EnglandOmaha$637K
- Adam BurdorfOmaha$313K
- Brian BoerOmaha$142K
- David JasperOmaha$128K
- Andrew RorieOmaha$61K
- Mohamed AhmedOmaha$57K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.